# Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer

> **NCT04362072** · PHASE4 · COMPLETED · sponsor: **Pfizer** · enrollment: 71 (actual)

## Conditions studied

- Carcinoma
- Non-Small-Cell Lung

## Interventions

- **DRUG:** Lorlatinib

## Key facts

- **NCT ID:** NCT04362072
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-29
- **Primary completion:** 2024-05-29
- **Final completion:** 2024-10-23
- **Target enrollment:** 71 (ACTUAL)
- **Last updated:** 2025-06-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04362072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04362072, "Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT04362072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*